Preoperative pulmonary hemodynamics and assessment of operability: Is there a pulmonary vascular resistance that precludes cardiac operation?

Pediatric Critical Care Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages

  Giglia, Therese M ^a   Humpl, Tilman ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cardiac transplantation; Elevated pulmonary vascular resistance; Pulmonary hypertension; Surgery for congenital heart disease

Indexed keywords

ISOPRENALINE;

CAVOPULMONARY CONNECTION; CHILD; CHILD CARE; CHRONIC LUNG DISEASE; CONFERENCE PAPER; CONGENITAL HEART DISEASE; CYANOSIS; FONTAN PROCEDURE; GENETIC PREDISPOSITION; HEART ATRIOVENTRICULAR VALVE; HEART CATHETERIZATION; HEART INJURY; HEART SINGLE VENTRICLE; HEART TRANSPLANTATION; HEART VALVE REGURGITATION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MORBIDITY; MORTALITY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; RISK FACTOR;

EID: 77949460226     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181d10cce     Document Type: Conference Paper

References (136)

1. Lacour-Gayet F, Clarke D, Jacobs J, et al: The Aristotle score: A complexity-adjusted method to evaluate surgical results. Eur J Cardiothorac Surg 2004; 25:911-924
2. Ma M, Gauvreau K, Allan CK, et al: Causes of death after congenital heart surgery. Ann Thorac Surg 2007; 83:1438-1445
3. Shaddy RE: Pulmonary hypertension in pediatric heart transplantation. Prog Pediatr Cardiol 2002; 11:131-136
4. Balzer DT, Kort HW, Day RW, et al: Inhaled nitric oxide as a preoperative test (INOP Test I): The INOP test study group. Circulation 2002; 106(12 Suppl 1):I76-I81
5. Kannan BR, Sivasankaran S, Tharakan JA, et al: Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J 2003; 55:161-166
6. Keane JF, Lock JE: Hemodynamic evaluation of congenital heart disease. In: Diagnostic and Interventional Catheterization in Congenital Heart Disease. Second Edition. Lock JE, Keane JF, Perry SB (Eds). Boston, Kluwer Academic Publishers, 2000, pp 37-72
7. Adatia I: Pulmonary vascular disease. In: The Natural and Modified History of Congenital Heart Disease. Freedom RM, Yoo S, Mikailian H, Williams WG (Eds). New York, Wiley-Blackwell, 2003, pp 518-527
8. Viswanathan S, Kumar RK: Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008; 71: 665-670
9. Whitehead KK, Gillespie MJ, Harris MA, et al: Noninvasive quantification of systemictopulmonary collateral flow: A major source of inefficiency in patients with superior cavopulmonary connections: Circ Cardiovasc Imaging 2009; 2:405-411
10. Grosse-Wortmann L, Al-Otay A, Yoo SJ: Aortopulmonary collaterals after bidirectional cavopulmonary connection or Fontan completion: Quantification with MRI. Circ Cardiovasc Imaging 2009; 2:219-225
11. DuShane JW, Krongrad E, Ritter DG, et al: The fate of raised pulmonary vascular resistance after surgery in ventricular septal defect. In: The Child with Congenital Heart Disease after Surgery. Rowe RD, Kidd BSL (Eds). Mount Kisco, NY, Futura Publishing Co., 1976
12. Rabinovitch M, Keane JF, Norwood WI, et al: Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984; 69: 655-667
13. Juaneda E, Haworth SG: Pulmonary vascular disease in children with truncus arteriosus. Am J Cardiol 1984; 54:1314-1320
14. Haworth SG: Pulmonary vascular bed in children with complete atrioventricular septal defect: Relation between structural and hemodynamic abnormalities. Am J Cardiol 1986; 57:833-839
15. Lock JE, Einzig S, Bass JL, et al: The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol 1982; 3:41-46
16. Steele PM, Fuster V, Cohen M, et al: Isolated atrial septal defect with pulmonary vascular obstructive disease-Long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76:1037-1042
17. Bush A, Busst CM, Haworth SG, et al: Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988; 59:480-485
18. Neutze JM, Ishikawa T, Clarkson PM, et al: Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol 1989; 63:327-331
19. Berner M, Beghetti M, Spahr-Schopfer I, et al: Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long- standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77:532-535
20. Atz AM, Adatia I, Lock JE, et al: Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33:813-819
21. Haworth SG, Radley-Smith R, Yacoub M: Lung biopsy findings in transposition of the great arteries with ventricular septal defect: Potentially reversible pulmonary vascular disease is not always synonymous with operability. J Am Coll Cardiol 1987; 9:327-333
22. Geggel RL, Mayer JE Jr, Fried R, et al: Role of lung biopsy in patients undergoing a modified Fontan procedure. J Thorac Cardiovasc Surg 1990;99:451-459
23. Yamaki S, Yasui H, Kado H, et al: Pulmonary vascular disease and operative indications in complete atrioventricular canal defect in early infancy. J Thorac Cardiovasc Surg 1993; 106:398-405
24. Maeda K, Yamaki S, Kado H, et al: Reevaluation of histomorphometric analysis of lung tissue in decision making for better patient selection for fontan-type operations. Ann Thorac Surg 2004; 78:1371-1381
25. Rosenzweig EB, Kerstein D, Barst RJ: Longterm prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
26. Frost AE, Quiñones MA, Zoghbi WA, et al: Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005; 24:501-503
27. Schwerzmann M, Zafar M, McLaughlin PR, et al: Atrial septal defect closure in a patient with " irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006; 110: 104-107
28. Khan IU, Ahmed I, Mufti WAL: Ventricular septal defect in infants and children with increased pulmonary vascular resistance and pulmonary hypertension-surgical management: Leaving an atrial level communication. J Ayub Med Coll Abbottabad 2006; 18:21-25
29. Zhou Q, Lai Y, Wei H: Unidirectional valve patch for repair of cardiac septal defects with pulmonary hypertension. Ann Thorac Surg 1995; 60:1245-1248
30. Ad N, Barak J, Birk E, et al: Unidirectional valve patch. Ann Thorac Surg 1996; 62: 626-628
31. Novick WM, Gurbuz AT, Watson DC, et al: Double patch closure of ventricular septal defect with increased pulmonary vascular resistance. Ann Thorac Surg 1998; 66: 1533-1538
32. Novick WM, Sandoval N, Lazorhysynets VV, et al: Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann Thorac Surg 2005; 79:21-28
33. Zhang B, Wu S, Liang J, et al: Unidirectional monovalve homologous aortic patch for repair of ventricular septal defect with pulmonary hypertension. Ann Thorac Surg 2007; 83:2176-2181
34. Khan SA, Gelb BD, Nguyen KH: Evaluation of pulmonary artery banding in the setting of ventricular septal defects and severely elevated pulmonary vascular resistance. Congenit Heart Dis 2006; 1:244-250
35. Thanopoulos BD, Tsaousis GS, Djukic M, et al: Transcatheter closure of high pulmonary artery pressure persistent ductus arteriosus with the Amplatzer muscular ventricular septal defect occlude. Heart 2002; 87: 260-263
36. Kepka C, Demkow M, Dzielińska Z, Ruzyllo W: [Transcatheter closure of wide, patent ductus arteriosus in an adult patient with severe pulmonary hypertension-A case report.] [Article in Polish] Kardiol Pol 2003; 59:517-518
37. Yan C, Zhao S, Jiang S, et al: Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart 2007; 93:514-518
38. Ji Q, Feng J, Mei Y, et al: Transcatheter closure of adult patent ductus arteriosus with severe pulmonary hypertension. Hypertens Res 2008; 31:1997-2002
39. Hirabayashi A, Miyaji K, Akagi T: Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension. Catheter Cardiovasc Interv 2009; 73:688-691
40. Li F, Xia W, Yuan S, et al: Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 2009; 30:363-3666
41. Kozik DJ, Tweddell JS: Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006; 81:S2347-S2354
42. Pearl JM, Schwartz SM, Nelson DP: Preoperative glucocorticoids decrease pulmonary hypertension in piglets after cardiopulmonary bypass and circulatory arrest. Ann Thorac Surg 2004; 77:994-1000
43. Checchia PA, Bronicki RA, Costello JM, et al: Steroid use before pediatric cardiac operations using cardiopulmonary bypass: An international survey of 36 centers. Pediatr Crit Care Med 2005; 6:441-444
44. Allen M, Sundararajan S, Pathan N, et al: Anti-inflammatory modalities: Their current use in pediatric cardiac surgery in the United Kingdom and Ireland. Pediatr Crit Care Med 2009; 10:341-345
45. Williams GD, Ramamoorthy C, Chu L, et al: Modified and conventional ultrafiltration during pediatric cardiac surgery: Clinical outcomes compared. J Thorac Cardiovasc Surg 2006; 132:1291-1298
46. Atz AM, Wessel DL: Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307-310
47. Murthy KS, Rao SG, Prakash KS, et al: Role of inhaled nitric oxide as a selective pulmonary vasodilator in pediatric cardiac surgical practice. Indian J Pediatr 1999; 66: 357-361
48. Chu CC, Lin SM, New SH, et al: Effect of milrinone on postbypass pulmonary hypertension in children after Tetralogy of Fallot repair. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:294-300
49. Wessel DL: Current and future strategies in the treatment of childhood pulmonary hypertension. Prog Pediatr Cardiol 2001; 12: 289-318
50. Macrae DJ, Field D, Mercier JC, et al: Inhaled nitric oxide therapy in neonates and children: Reaching a European consensus. Intensive Care Med 2004; 30:372-380
51. Zimmerman AT, Ibsen LM: Advances in postoperative care of pediatric cardiac patients. Curr Opin Anaesthesiol 2004; 17: 241-246
52. Kawai T, Wada Y, Enmoto T, et al: Comparison of hemodynamic data before and after corrective surgery for Down's syndrome and ventricular septal defect. Heart Vessels 1995; 10:154-157
53. Suzuki K, Yamaki S, Mimori S, et al: Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 2000; 86:434-437
54. Cannon BC, Feltes TF, Fraley JK, et al: Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: Factors related to nitric oxide response. Pediatr Cardiol 2005; 26:565-569
55. Kageyama K, Hashimoto S, Nakajima Y, et al: The change of plasma endothelin-1 levels before and after surgery with or without Down syndrome. Paediatr Anaesth 2007; 17:1071-1077
56. Cua CL, Blankenship A, North AL, et al: Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007; 28: 250-254
57. Reller MD, Morris CD: Is Down syndrome a risk factor for poor outcome after repair of congenital heart defects? J Pediatr 1998; 132:738-741
58. Wada N, Takahashi Y, Ando M, et al: Single ventricle repair in children with Down's syndrome. Gen Thorac Cardiovasc Surg 2008; 56:104-108
59. Deng Z, Morse JH, Slager SL: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744
60. Janssen B, Rindermann M, Barth U, et al: Linkage analysis in a large family with primary pulmonary hypertension: genetic heterogeneity and a second primary pulmonary hypertension locus on 2q31-32. Chest 2002; 121(3 Suppl):54S-56S
61. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006; 114:1417-1431
62. Fredenburgh LE, Liang OD, Macias AA, et al: Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 2008; 117: 2114-2122
63. Rabinovitch M: Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118:2372-2379
64. Atkinson C, Stewart S, Upton PD, et al: Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105: 1672-1678
65. International PPH Consortium, Lane KB, Machado RD, et al: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26:81-84
66. Machado RD, Pauciulo MW, Thomson JR, et al: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68:92-102
67. Roberts KE, McElroy JJ, Wong WP, et al: BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004; 24:371-374
68. Rosenzweig EB, Morse JH, Knowles JA, et al: Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27:668-674
69. Canter JA, Summar ML, Smith HB, et al: Genetic variation in the mitochondrial enzyme carbamyl-phosphate synthetase I predisposes children to increased pulmonary artery pressure following surgical repair of congenital heart defects: A validated genetic association study. Mitochondrion 2007; 7:204-210
70. Hoffman GM, Tweddell JS, Ghanayem NS, et al: Alteration of the critical arteriovenous oxygen saturation relationship by sustained afterload reduction after the Norwood procedure. J Thorac Cardiovasc Surg 2004; 127:738-745
71. Graham EM, Bradley SM, Atz AM: Preoperative management of hypoplastic left heart syndrome. Expert Opin Pharmacother 2005; 6:687-693
72. Wernovsky G, Ghanayem N, Ohye RG, et al: Hypoplastic left heart syndrome: consensus and controversies in 2007. Cardiol Young 2007; 17(Suppl 2):75-86
73. Guzzetta NA: Phenoxybenzamine in the treatment of hypoplastic left heart syndrome: a core review. Anesth Analg 2007; 105:312-315
74. Mastropietro CW, Clark JA, Delius RE, et al: Arginine vasopressin to manage hypoxemic infants after stage I palliation of single ventricle lesions. Pediatr Crit Care Med 2008; 9:506-510
75. Furck AK, Hansen JH, Uebing A, et al: The impact of afterload reduction on the early postoperative course after the Norwood operation-A 12-year single-centre experience. Eur J Cardiothorac Surg 2010; 37: 289-295
76. Shekerdemian L: Perioperative manipulation of the circulation in children with congenital heart disease. Heart 2009; 95: 1286-1296
77. Migliavacca F, Pennati G, Dubini G, et al: Modeling of the Norwood circulation: effects of shunt size, vascular resistances, and heart rate. Am J Physiol Heart Circ Physiol 2001; 280:H2076-H2086
78. Graziano JN, Heidelberger KP, Ensing GJ, et al: The influence of a restrictive atrial septal defect on pulmonary vascular morphology in patients with hypoplastic left heart syndrome. Pediatr Cardiol 2002; 23: 146-151
79. Rychik J, Rome JJ, Collins MH, et al: The hypoplastic left heart syndrome with intact atrial septum: Atrial morphology, pulmonary vascular histopathology and outcome. J Am Coll Cardiol 1999; 34:554-560
80. Gibbs JL, Wren C, Watterson KG, et al: Stenting of the arterial duct combined with banding of the pulmonary arteries and atrial septectomy or septostomy: A new approach to palliation for the hypoplastic left heart syndrome. Br Heart J 1993; 69: 551-555
81. Galantowicz M, Cheatham JP: Lessons learned from the development of a new hybrid strategy for the management of hypoplastic left heart syndrome. Pediatr Cardiol 2005; 26:190-199
82. Lim DS, Peeler BB, Matherne GP, et al: Risk-stratified approach to hybrid transcatheter- surgical palliation of hypoplastic left heart syndrome. Pediatr Cardiol 2006; 27:91-95
83. Bacha EA, Daves S, Hardin J, et al: Singleventricle palliation for high-risk neonates: The emergence of an alternative hybrid stage I strategy. J Thorac Cardiovasc Surg 2006; 131:163-171.e2
84. Artrip JH, Campbell DN, Ivy DD, et al: Birth weight and complexity are significant factors for the management of hypoplastic left heart syndrome. Ann Thorac Surg 2006; 82:1252-1257; discussion, 1258-1259
85. Caldarone CA, Benson L, Holtby H, et al: Initial experience with hybrid palliation for neonates with single-ventricle physiology. Ann Thorac Surg 2007; 84:1294-1300
86. Akintürk H, Michel-Behnke I, Valeske K, et al: Hybrid transcatheter-surgical palliation: basis for univentricular or biventricular repair: The Giessen experience. Pediatr Cardiol 2007; 28:79-87
87. Cua CL, Galantowicz ME, Turner DR, et al: Palliation via hybrid procedure of a 1.4-kg patient with a hypoplastic left heart. Congenit Heart Dis 2007; 2:191-193
88. Pizarro C, Derby CD, Baffa JM, et al: Improving the outcome of high-risk neonates with hypoplastic left heart syndrome: Hybrid procedure or conventional surgical palliation? Eur J Cardiothorac Surg 2008; 33: 613-618
89. Galantowicz M, Cheatham JP, Phillips A, et al: Hybrid approach for hypoplastic left heart syndrome: Intermediate results after the learning curve. Ann Thorac Surg 2008; 85:2063-2070; discussion, 2070-2071
90. Vlahos AP, Lock JE, McElhinney DB, et al: Hypoplastic left heart syndrome with intact or highly restrictive atrial septum: outcome after neonatal transcatheter atrial septostomy. Circulation 2004; 109:2326-2330
91. Choussat A, Fontan F, Besse P, et al: Selection criteria for Fontan's procedure. In: Pediatric Cardiology. Anderson RH, Shinebourne EA (Eds). Edinburgh, Scotland, Livingstone, 1978, pp 559-566
92. Bridges ND, Lock JE, Castaneda AR: Baffle fenestration with subsequent transcatheter closure. Modification of the Fontan operation for patients at increased risk. Circulation 1990; 82:1681-1689
93. Mavroudis C, Zales VR, Backer CL, et al: Fenestrated Fontan with delayed catheter closure. Effects of volume loading and baffle fenestration on cardiac index and oxygen delivery. Circulation 1992; 86(5 Suppl): II85-II92
94. Gentles TL, Mayer JE Jr, Gauvreau K, et al: Fontan operation in five hundred consecutive patients: Factors influencing early and late outcome. J Thorac Cardiovasc Surg 1997; 114:376-391
95. Hosein RB, Clarke AJ, McGuirk SP, et al: Factors influencing early and late outcome following the Fontan procedure in the current era. The 'Two Commandments'? Eur J Cardiothorac Surg 2007; 31:344-352; discussion, 353
96. Driscoll DJ, Offord KP, Feldt RH, et al: Fiveto fifteen-year follow-up after Fontan operation. Circulation 1992; 85:469-496
97. Knott-Craig CJ, Danielson GK, Schaff HV, et al: The modified Fontan operation. An analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg 1995; 109:1237-1243
98. Kaulitz R, Ziemer G, Luhmer I, et al: Modified Fontan operation in functionally univentricular hearts: Preoperative risk factors and intermediate results. J Thorac Cardiovasc Surg 1996; 112:658-664
99. Yoshimura N, Yamaguchi M, Oshima Y, et al: Risk factors influencing early and late mortality after total cavopulmonary connection. Eur J Cardiothorac Surg 2001; 20: 598-602
100. Burkhart HM, Dearani JA, Mair DD, et al: The modified Fontan procedure: Early and late results in 132 adult patients. J Thorac Cardiovasc Surg 2003; 125:1252-1259
101. Malhotra SP, Ivy DD, Mitchell MB, et al: Performance of cavopulmonary palliation at elevated altitude: midterm outcomes and risk factors for failure. Circulation 2008; 118(14 Suppl):S177-S181
102. Scherrer U, Turini P, Thalmann S, et al: Pulmonary hypertension in high-altitude dwellers: Novel mechanisms, unsuspected predisposing factors. Adv Exp Med Biol 2006; 588:277-291
103. Kraus M, Molinari L, Arbenz U, et al: [Indications criteria for total cavopulmonary anastomosis (Fontan operation).] [Article in German.] Schweiz Med Wochenschr 1999; 129:793-798
104. Ghanayem NS, Berger S, Tweddell JS: Medical management of the failing Fontan. Pediatr Cardiol 2007; 28:465-471
105. Lévy M, Danel C, Laval AM, et al: Nitric oxide synthase expression by pulmonary arteries: A predictive marker of Fontan procedure outcome? J Thorac Cardiovasc Surg 2003; 125:1083-1090
106. Rothman A, Mayer JE, Freed MD" Treatment of chronic pleural effusions after the Fontan procedure with prednisone. Am J Cardiol 1987; 60:408-409
107. Bridges ND, Jonas RA, Mayer JE, et al: Bidirectional cavopulmonary anastomosis as interim palliation for high-risk Fontan candidates. Early results. Circulation 1990; 82(5 Suppl):IV170-IV176
108. Albanese SB, Carotti A, Di Donato RM, et al: Bidirectional cavopulmonary anastomosis in patients under two years of age. J Thorac Cardiovasc Surg 1992; 104:904-909
109. Pridjian AK, Mendelsohn AM, Lupinetti FM, et al: Usefulness of the bidirectional Glenn procedure as staged reconstruction for the functional single ventricle. Am J Cardiol 1993; 71:959-962
110. Gross GJ, Jonas RA, Castaneda AR, et al: Maturational and hemodynamic factors predictive of increased cyanosis after bidirectional cavopulmonary anastomosis. Am J Cardiol 1994; 74:705-709
111. Lamberti JJ, Mainwaring RD, Spicer RL, et al: Factors influencing perioperative morbidity during palliation of the univentricular heart. Ann Thorac Surg 1995; 60(6 Suppl):S550-S553
112. Alejos JC, Williams RG, Jarmakani JM, et al: Factors influencing survival in patients undergoing the bidirectional Glenn anastomosis. Am J Cardiol 1995; 75:1048-1050
113. Reddy VM, McElhinney DB, Moore P, et al: Outcomes after bidirectional cavopulmonary shunt in infants less than 6 months old. J Am Coll Cardiol 1997; 29: 1365-1370
114. Masuda M, Kado H, Shiokawa Y, et al: Clinical results of the staged Fontan procedure in high-risk patients. Ann Thorac Surg 1998; 65:1721-1725
115. Day RW, Etheridge SP, Veasy LG, et al: Single ventricle palliation: greater risk of complications with the Fontan procedure than with the bidirectional Glenn procedure alone. Int J Cardiol 2006; 106: 201-210
116. Silvilairat S, Pongprot Y, Sittiwangkul R, et al: Factors influencing survival in patients after bidirectional Glenn shunt. Asian Cardiovasc Thorac Ann 2008; 16:381-386
117. Hussain A, Arfi AM, Hussamuddin M, et al: Comparative outcome of bidirectional Glenn shunt in patients with pulmonary vascular resistance > or = 3.5 woods units versus <3.5 woods units. Am J Cardiol 2008; 102:907-912
118. Varma C, Warr MR, Hendler AL, et al: Prevalence of " silent" pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol 2003; 41:2252-2258
119. Bradley SM, Mosca RS, Hennein HA, et al: Bidirectional superior cavopulmonary connection in young infants. Circulation 1996; 94(9 Suppl):II5-II11
120. Bradley SM, Simsic JM, Mulvihill DM: Hypoventilation improves oxygenation after bidirectional superior cavopulmonary connection. J Thorac Cardiovasc Surg 2003; 126:1033-1039
121. Hoskote A, Li J, Hickey C, et al: The effects of carbon dioxide on oxygenation and systemic, cerebral, and pulmonary vascular hemodynamics after the bidirectional superior cavopulmonary anastomosis. J Am Coll Cardiol 2004; 44:1501-1509
122. Adatia I, Atz AM, Wessel DL: Inhaled nitric oxide does not improve systemic oxygenation after bidirectional superior cavopulmonary anastomosis. J Thorac Cardiovasc Surg 2005; 129:217-219
123. Kirklin JK, Naftel DC, Kirklin JW, et al: Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7:331-336
124. Murali S, Kormos RL, Uretsky BF, et al: Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: The Pittsburgh experience. Am Heart J 1993; 126:896-904
125. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al: Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:549-562
126. Mudge GH, Goldstein S, Addonizio LJ, et al: 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol 1993; 22:21-31
127. Costanzo MR, Augustine S, Bourge R, et al: Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92:3593-3612
128. Zales VR, Pahl E, Backer CL, et al: Pharmacologic reduction of pretransplantation pulmonary vascular resistance predicts outcome after pediatric heart transplantation. J Heart Lung Transplant 1993; 12:965-972
129. Gajarski RJ, Towbin JA, Bricker JT, et al: Intermediate follow-up of pediatric heart transplant recipients with elevated pulmonary vascular resistance index. J Am Coll Cardiol 1994; 23:1682-1687
130. Bando K, Konishi H, Komatsu K, et al: Improved survival following pediatric cardiac transplantation in high-risk patients. Circulation 1993; 88:II218-II223
131. Canter CE, Shaddy RE, Bernstein D, et al: Indications for heart transplantation in pediatric heart disease: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Car- diovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115:658 - 676. Erratum in: Circulation 2007; 115:e385
132. Canter CE: Preoperative assessment and management of pediatric heart transplantation. Prog Pediatr Cardiol 2000; 11:91-97
133. Haddad H, Elabbassi W, Moustafa S, et al: Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension. ASAIO J 2005; 51:456-460
134. Andrea G, Giuseppe B, Tiziano C, et al: Is fixed severe pulmonary hypertension still a contraindication to heart transplant in the modern era of mechanical circulatory support? A review. J Cardiovasc Med (Hagerstown) 2008; 9:1059-1062
135. Kao B, Balzer DT, Huddleston CB, et al: Long-term prostacyclin infusion to reduce pulmonary hypertension in a pediatric cardiac transplant candidate prior to transplantation. J Heart Lung Transplant 2001; 20:785-788
136. Gandhi SK, Grady RM, Huddleston CB, et al: Beyond Berlin: Heart transplantation in the " untransplantable." J Thorac Cardiovasc Surg 2008; 136:529-531